|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
The objective of this study was to test the hypothesis that accumulated helper T lymphocytes in malignant pleural effusions may shift
to T-helper type 2 (Th2) and produce soluble ST2 protein. We took
samples of serum and pleural effusions (p-) from patients with carcinomatous pleurisy (CA, n = 17), tuberculous pleurisy (TB, n = 8),
and congestive heart failure (HF, n = 5) and compared the concentration of cytokines or ST2. Ex vivo production of interleukin (IL)-4 and IL-10, though not that of interferon (IFN)-
or IL-12, from
CD4+ T cells isolated from pleural effusions was higher in the CA group than in the TB or HF group. The p-ST2 concentrations were significantly higher in the CA group than in the TB or HF group, positively correlated with the percentage of pleural effusion CD4+
T cells (r = 0.432, p = 0.016) and inversely correlated with p-IFN-
concentrations (r =
0.423, p = 0.019). Furthermore, mRNA expression of ST2 in CD4+ T cells isolated from group CA was upregulated, compared with that in those isolated from the TB group.
These results suggest that CD4+ T cells in CA shift to Th2, which
can produce soluble ST2 protein, resulting in increased concentrations of p-ST2 in malignant pleural effusion.
| |
INTRODUCTION |
|---|
|
|
|---|
Keywords: ST2; lung cancer; pleural effusion; helper T lymphocyte type 2
An accumulation of lymphocytes, especially helper T lymphocytes, in pleural fluid frequently occurs in neoplastic effusions secondary to direct pleural involvement and/or metastases
from malignancies (1, 2). It is thought that the cytokines released from the accumulated lymphocytes may play some role
in the interaction between lymphocytes and tumor cells in malignant pleural effusions (3, 4). Shimokata and colleagues
demonstrated that low concentrations of interleukin (IL)-2
and interferon (IFN)-
were found in malignant effusions, especially when compared with concentrations of these cytokines in tuberculous pleurisy (TB) (5). Chen and coworkers reported impairment of local cellular immunity with increased IL-10 and undetectable IL-12 in neoplastic pleural effusions
(6). In addition, Nakamura and associates demonstrated that
eosinophilia in the pleural fluid induced by intrapleural administration of IL-2 to patients with malignant pleurisy was
due to the eosinophil colony-stimulating factor activities of
various components, including IL-5, IL-3, and granulocyte/
macrophage colony-stimulating factor (7). These findings suggest that in malignant pleural effusions, local immune reactions may likely favor the T-helper type 2 (Th2) pathway over
the Th1 pathway.
Three distinct types of ST2 gene products, a soluble secreted form (ST2), a transmembrane receptor form (ST2L), and a variant form (ST2V), have been cloned (8-10). The ST2 gene, also known as T1, Fit-1, and DER4, was originally identified as a gene induced by serum stimulation of fibroblasts (8, 11-13) and has recently been demonstrated to be overexpressed preferentially on Th2 effector cells but not on Th1 cells (14, 15). Furthermore, in a murine model of Th2-dependent allergic airway inflammation, administration of a neutralizing antibody against ST2 partially inhibited the development of Th2 effector functions in vivo (16, 17). We recently demonstrated that serum human ST2 concentrations in subjects with asthma were more significantly increased than those in healthy control subjects (18). Therefore, ST2 seems to play an essential role in the development of Th2 responses in pathologic conditions.
These findings suggesting that ST2 expression is critical for Th2 responses led us to evaluate the relationship between ST2 expression and Th2 dominance of effusion-associated lymphocytes in malignant effusion. We recently generated an enzyme-linked immunosorbent assay (ELISA) system to quantify the soluble form of ST2 protein (19). In the present study, using this system, we measured ST2 protein concentrations in the sera and pleural effusions of patients with carcinomatous pleurisy (CA) and compared them with those of patients with TB, which obviously favors a Th1-like immune response (20, 21). The results demonstrated that pleural ST2 concentrations in CA were significantly higher than those in TB. Th2 dominance and ST2 gene expression of CD4+ lymphocytes isolated from malignant pleural effusions were also analyzed in this study.
| |
METHODS |
|---|
|
|
|---|
Subjects
The study protocol was approved by our institutional review board for human studies, and informed consent was obtained from all subjects. The study sample consisted of 30 patients, for whom a definitive diagnosis was ultimately reached (CA, n = 17; TB, n = 8; congestive heart failure [HF], n = 5). The diagnostic criteria used were described previously (21). The primary lesions in all cases of CA proved to be histologically confirmed lung carcinoma (adenocarcinoma, 9 cases; squamous cell carcinoma, 4; small cell carcinoma, 2; large cell carcinoma, 2). Pleural effusions were defined as exudative or transudative, using Light's criteria (22).
Preparation of Mononuclear Cells and Determination of Lymphocyte Subpopulations in Pleural Effusion
Pleural effusion specimens were collected from all subjects. Each sample was examined for the total cell number and differential cell counts. Lymphocytes were separated from pleural effusion cells by centrifugation on a discontinuous Percoll (Pharmacia, Uppsala, Sweden) density gradient as previously described (23) and were processed for flow cytometry to determine lymphocyte phenotype. Fluorescein isothiocyanate or phycoerythrin-conjugated monoclonal antibodies (anti-IgG1, -IgG2a, -CD3, -CD4, -CD8, -CD20, -CD56) were purchased from the supplier and used according to the manufacturer's protocol to detect the corresponding surface antigens (Becton Dickinson, Mountain View, CA). The antigen immunofluorescence of the cells was analyzed by a FACstar Plus Cytofluorometer (Becton Dickinson).
Ex Vivo Cytokine Production of CD4+ T Lymphocytes Isolated from Pleural Effusion
CD4+ T cells were isolated from mononuclear cells in pleural effusion
using a MACS CD4+ cell isolation system according to the manufacturer's protocol (Miltenyi Biotech., Auburn, CA), and the cell viability was greater than 95% as determined by Trypan blue dye exclusion
test. The isolated CD4+ T cells were cultured for six hours at 5 × 106
cells/ml in RPMI 1640 medium in the absence or presence of phorbol myristate acetate (PMA, 50 ng/ml) and Ca ionophore (200 ng/ml), and
the supernatants were frozen at
80° C until assay.
Measurement of Human ST2 Protein and Cytokine Concentrations
The concentration of soluble human ST2 protein in serum and in
pleural effusions was measured by a sandwich ELISA we developed previously (19). The quantification of IFN-
, IL-4, IL-10, and IL-12
production in sera, pleural effusions, and a conditioned medium of
cultured lymphocytes was performed by a sandwich ELISA (BioSource, Inc., Camarillo, CA).
Analysis of mRNA Expression for Human ST2 by Reverse Transcription-Polymerase Chain Reaction
Total cellular RNA was extracted from isolated CD4+ T cells using Trizol reagent (Life Technologies, Inc., Gaithersburg, MD). Five hundred
nanograms of RNA was reverse transcribed and amplified by reverse
transcription-polymerase chain reaction (RT-PCR; Takara, Tsukuba,
Japan) under the following conditions: 94° C, one minute; 57° C, one
minute; and 72° C, one minute, for 36 cycles. The PCR products of ST2
and
-actin are fragments 659 and 547 bp in length, respectively.
Statistical Analysis
Data were expressed as mean ± SEM. Multiple comparisons were performed by one-way factorial analysis of variance (ANOVA) with post hoc tests. The correlation of ST2 concentrations with several variables was conducted using Pearson's correlation test. p < 0.05 was considered statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Characteristics and Lymphocyte Subpopulations in Pleural Effusions of Each Group
Total and differential cell counts in each group of subjects in the present study are summarized in Table 1. Subjects with TB showed a marked elevation of total cell counts, and a large proportion of these cells was lymphocytes, with some macrophages and neutrophils. Subjects with CA showed a large proportion of lymphocytes and macrophages in the pleural space. Importantly, on cytologic examination, malignant cells were found in 15 subjects. Subjects with transudative effusions secondary to HF showed a predominance of lymphocytes without sequestration of neutrophils or macrophages in the pleural space.
|
The dominant cell type within pleural fluids is lymphocytes. Absolute lymphocyte counts evidenced the highest values in TB, showing a significant increase in comparison with absolute lymphocyte counts in CA (p < 0.0001) and in HF (p < 0.0001) (Table 2). Evaluation of the lymphocyte subpopulation in pleural effusions of different etiologies showed that T cells, especially CD4+ T cells, were dominant in all situations. More specifically, a significant rise of CD4+ T cells and a significant decrease of CD8+ or CD56+ cells were observed in CA in comparison with TB (Table 2).
|
Cytokine Concentrations in the Sera and Pleural Fluid
The concentrations of IFN-
, IL-4, IL-10, and IL-12 in the sera
and pleural fluid in the CA, TB, and HF groups were measured by ELISA. IFN-
concentrations in pleural fluids (p-IFN-
) were significantly higher in the TB group than in the CA or HF group (p < 0.0005, Figure 1A), whereas no significant differences in serum IFN-
(s-IFN-
) concentrations were observed among the
three groups (mean s-IFN-
± SEM: CA, 3.5 ± 0.9 pg/ml; TB,
3.0 ± 1.0 pg/ml; HF, 3.5 ± 0.8 pg/ml). No significant differences in
the IL-10 concentrations in sera (s-IL-10) or pleural fluid (p-IL-10) were observed among the three groups (mean s-IL-10 ± SEM: CA, 2.3 ± 1.1 pg/ml; TB, 2.0 ± 1.2 pg/ml; HF, 1.5 ± 0.9 pg/ml; p-IL-10: Figure 1B). The IL-4 concentrations in sera
(s-IL-4) and pleural fluid (p-IL-4) were very low in all three
groups, and no statistically significant differences were found in
s-IL-4 or p-IL-4 concentrations among the groups (mean s-IL-4 ± SEM: CA, 2.2 ± 0.7 pg/ml; TB, 2.1 ± 0.2 pg/ml; HF, 2.1 ± 0.6 pg/ml; p-IL-4: Figure 1C). The IL-12 concentrations were below
the minimal limits of detection in the sera and the pleural fluid in
all groups (data not shown).
|
Ex Vivo Cytokine Production by CD4+ T Cells Isolated from Pleural Effusions
Cytokine production in a conditioned medium of CD4+ T
cells (5 × 106 cells isolated from pleural effusions) cultured
with or without PMA/Ca ionophore was compared among all
groups (Figure 2). The concentration of IFN-
produced by
CD4+ T cells from the TB group was significantly higher than
that from the CA or HF group (p < 0.0001) when these cells
were stimulated with PMA/Ca ionophore (Figure 2A). In contrast, the level of IL-10 secretion from CD4+ T cells in the
presence of PMA/Ca ionophore was considerably greater in
the CA group than in the TB or HF group (p < 0.0001, Figure
2B). Likewise, the IL-4 level produced by these cells (stimulated with PMA/Ca ionophore) derived from the CA group
was statistically higher than that from the TB (p < 0.005) or
HF group (p < 0.05) (Figure 2C). IL-12 concentrations in the
supernatant were undetectable in all groups (data not shown).
|
Distribution of Soluble ST2 Concentrations in the Sera and Pleural Effusions
A total of 60 samples (1 serum and 1 pleural fluid sample per subject) was taken from the 30 subjects (CA, n = 17; TB, n = 8; HF, n = 5). The distributions of soluble ST2 concentrations in the sera and pleural effusions of each group are shown in Figure 3. No significant differences in serum ST2 (s-ST2) concentrations were observed among the three groups (Figure 3A), but the ST2 concentration in the pleural effusions (p-ST2) of the CA group was significantly higher than that in those of the TB (p < 0.001) or HF group (p < 0.01) (Figure 3B).
|
Correlation of p-ST2 Concentrations with Cell Populations or Cytokine Concentrations in Pleural Effusions
The correlation of p-ST2 concentrations with cell populations
or cytokine concentrations in subjects with pleural effusion was analyzed using Pearson's correlation coefficient (Figure
4). The p-ST2 concentrations did not correlate with the percentage and absolute cell number of lymphocytes in pleural
effusions. p-ST2 concentrations were significantly correlated
with the percentage of CD4+ T cells, but not with the absolute
cell number of CD4+ T cells, in pleural effusions. Further, a
statistically significant inverse correlation was observed between the p-ST2 and the p-IFN-
concentrations, whereas no
correlation was found between the p-ST2 and p-IL-10 concentrations.
|
mRNA Expression of ST2 in CD4+ T Cells Isolated from Pleural Effusions
We analyzed the expression of human ST2 mRNA in CD4+ T cells isolated from malignant and tuberculous pleural effusions (Figure 5A). The expression of ST2 mRNA in the CA group was significantly upregulated in comparison with that in the TB group (p < 0.001, Figure 5B).
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we investigated the dominant subset of helper T
cells in malignant pleural effusions and determined the soluble ST2 concentrations in the sera and pleural fluid of subjects
with CA, TB, and HF, respectively. The results demonstrated
that effusion-associated CD4+ lymphocytes in CA, which produced IL-4 and IL-10 ex vivo but did not produce IFN-
or IL-12, thus polarized preferentially to Th2 cells and that p-ST2
concentrations were significantly higher in the CA group than
in the TB or HF group.
Human immunity has been found to have two major components, cellular immunity and humoral immunity. The Th1
pathway favors cellular immunity, whereas the Th2 pathway
favors humoral immunity (24). Th1 cells produce IL-2, IFN-
,
and tumor necrosis factor-
, whereas Th2 cells produce IL-4,
IL-5, and IL-10 (24). Although lack of cellular immunity has
been reported in malignant pleural effusions (6), thus far there
have been very few reports analyzing lymphocyte subtypes in
these effusions from the viewpoint of Th1/Th2 balance. Some
reports have demonstrated that the IL-10 concentrations in
malignant pleural effusions increased significantly as compared with those in sera, whereas the IL-12 concentrations
were below minimal detectable concentrations in both the sera
and effusions, and suggested that helper T cells in malignant
pleural effusions may be Th2-dominant (7, 23). However, comparative studies have found no significant difference between
subjects with tuberculosis and cancer regarding p-IL-10 concentrations, though p-IFN-
concentrations were found to be
higher in TB than in malignant pleurisy (25, 26), as was also
shown in our results (Figure 1B). Furthermore, because cancer
cells and macrophages as well as helper T cells may produce
IL-10 (27, 28), increased concentrations of IL-10 in an effusion
do not directly indicate Th2 dominance in lymphocytes. To address these issues, we analyzed ex vivo cytokine production by
CD4+ T cells isolated from effusions caused by CA, TB, and
HF and compared the concentrations of these cytokines among
these three groups. Our results clearly demonstrated that CD4+
T cells isolated from CA effusions, stimulated with PMA/Ca
ionophore, produced higher amounts of IL-4 and IL-10 than did
the effusions from the TB or HF group, whereas IFN-
was more
significantly produced by CD4+ T cells from effusions of the
TB group than from those of the CA or HF group. These results strongly suggest that CD4+ T cells present in malignant
pleural effusions are Th2-dominant (but may not be activated
enough to produce Th2 cytokines spontaneously). In contrast,
CD4+ T cells in tuberculous pleural effusions are Th1-dominant and may be activated enough to produce Th1 cytokines, because p-IFN-
concentrations were higher in the TB group, and
ex vivo production of IFN-
by CD4+ T cells in the TB group
was more significant even without stimulation, compared with
those in the CA or HF group.
Because ST2 has been reported to be preferentially expressed on Th2 in murine cell lines (14, 15), Th2 dominance in lymphocytes of malignant pleural effusions led us to analyze the concentrations of the soluble form of ST2 protein in the effusions. As we expected, our results demonstrated that p-ST2 concentrations in the CA group were significantly higher than those in the TB or HF group. Further, the ST2 mRNA expression of CD4+ T cells isolated from CA effusions was upregulated compared with that from the TB group. These results suggest that increased production of ST2 may be derived from Th2 cells, which are dominant among the CD4+ T cells in malignant pleural effusions.
Upon encountering an antigen, the naive CD4+ T helper
precursor (Thp) cells enact a specific genetic process that results in differentiation toward the Th1 or Th2 lineage. This differentiation process can be influenced by antigen concentration, through the ligation of costimulatory molecules, and by
cytokines (29). It is thought that pleural effusion is a good
model by which to understand the direct interaction between
immune cells and antigen (pathogen or tumor antigen), and the
role of cytokines in it for Th differentiation, on the basis of the
fact that a pleural effusion resulting from cancer presents an
environment in which both effector lymphocytes and target
tumor cells coexist in a defined space. Our results demonstrating that CD4+ lymphocytes in a malignant pleural effusion produced IL-4 and IL-10 ex vivo, but not IFN-
or IL-12, suggest
that impairment of the Th1-mediated immune response, which is
essential for antitumor immunity, results in a progression of
cancer to the pleural cavity and a subsequent accumulation of
effusion. IL-10 has various immunosuppressive effects on T cells
(30), whereas IL-12 has an obligatory role for the induction of
Th1 cells and for the differentiation and activation of natural
killer cells and cytotoxic T cells (31, 32). Lymphocytes infiltrating
the pleural cavity may be susceptible to local stimulation by these
cytokines. Increased IL-10 and undetectable IL-12 in the malignant pleural effusions observed in our study are consistent
with the findings of suppressed antitumor immunity in effusions (3, 4, 6, 23). Furthermore, an increase of p-ST2 suggests
depression of the Th1-mediated antitumor immune response
in malignant pleural effusions. This is supported by our findings here that ST2 (released dominantly from Th2 cells) concentrations inversely correlated with IFN-
(for Th1-mediated immune response) concentrations in pleural effusions.
In addition to its relationship to antitumor immunity in malignant pleurisy, the Th1/Th2 cytokine balance in the pleural
space plays another important role in the pathophysiologic
process of pleural disease. The development of pleural effusions is associated with the presence of an increased number
of inflammatory and immune cells in the pleural space (1, 2).
Different disease entities are typically associated with the predominance of a certain cell type in this lesion (1, 2, 22). Antony and colleagues demonstrated that Th1 and Th2 cytokines
influenced C-C chemokine (macrophage inflammatory protein 1
and monocyte chemoattractant protein 1) expression
in pleural mesothelial cells and thus regulated the mononuclear cell migration into pleural space in TB (33). Various cells
present in the pleural space may produce various cytokines or
chemokines that contribute to the progress of pleural effusion
(7, 26-28, 33, 34). It is important to further analyze the effect
of the Th1/Th2 cytokine balance on the regulation of cytokine
and chemokine production from the pleural effusion cells and
the subsequent recruitment of inflammatory and immune cells
to the pleural space.
In conclusion, our results showed that the p-ST2 concentrations in the CA group were significantly elevated and that CD4+ helper T cells present in malignant pleural effusions were relatively shifted to the Th2 lineage and significantly expressed ST2 mRNA. These findings suggest that elevation of ST2 may reflect Th2 dominance, which may subsequently suppress antitumor immunity in malignant pleural effusions. Further elucidation of the biologic and pathologic function of ST2 in pleural effusions will provide insight into the immunopathologic characteristics of malignant pleural effusions.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Katsuhisa Oshikawa, Department of Pulmonary Medicine, Jichi Medical School, 3311 Minamikawachi, Kawachi-gun, Tochigi, 329-0498, Japan. E-mail: oshikatu{at}jichi.ac.jp
(Received in original form May 3, 2001 and accepted in revised form January 15, 2002).
Acknowledgments: The authors thank Ms. Tomoko Ikahata for her excellent technical assistance.
This study was supported by departmental funds of the Jichi Medical School and a grant (13670612) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
| |
References |
|---|
|
|
|---|
1. Sahn SA. The pleura. Am Rev Respir Dis 1988; 138: 184-234 [Medline].
2. Light RW. Pleural diseases. Dis Mon 1992; 38: 261-331 [Medline].
3. Weissler JC, Nicod LP, Toews GB. Pulmonary natural killer cell activity is reduced in patients with bronchogenic carcinoma. Am Rev Respir Dis 1987; 135: 1353-1357 [Medline].
4.
Blanchard DK,
Kavanagh JJ,
Sinkovics JG,
Cavanagh D,
Hewitt SM,
Djeu JY.
Infiltration of interleukin-2-inducible killer cells in ascitic
fluid and pleural effusions of advanced cancer patients.
Cancer Res
1988;
48:
6321-6327
5.
Shimokata K,
Saka H,
Murate T,
Hasegawa Y,
Hasegawa T.
Cytokine
content in pleural effusion: comparison between tuberculous and carcinomatous pleurisy.
Chest
1991;
99:
1103-1107
6.
Chen YM,
Yang WK,
Whang-Peng J,
Kuo BI,
Perng RP.
Elevation of interleukin-10 levels in malignant pleural effusion.
Chest
1996;
110:
433-436
7. Nakamura Y, Ozaki T, Yanagawa H, Yasuoka S, Ogura T. Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy. Am J Respir Cell Mol Biol 1990; 34: 291-300 .
8. Tominaga S. A putative protein of a growth specific cDNA from BALB/ c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989; 258: 301-304 [Medline].
9. Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett 1993; 318: 83-87 [Medline].
10. Tominaga S, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 1999; 264: 14-18 [Medline].
11.
Werenskiold AK,
Hoffmann S,
Klemenz R.
Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3
fibroblasts.
Mol Cell Biol
1989;
9:
5207-5214
12. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994; 13: 1176-1188 [Medline].
13.
Lanahan A,
Williams JB,
Sanders LK,
Nathans D.
Growth factor-induced
delayed early response genes.
Mol Cell Biol
1992;
12:
3919-3929
14.
Yanagisawa K,
Naito Y,
Kuroiwa K,
Arai T,
Furukawa Y,
Tomizuka H,
Miura Y,
Kasahara T,
Tetsuka T,
Tominaga S.
The expression of ST2
gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells.
J Biochem (Tokyo)
1997;
121:
95-103
15.
Xu D,
Chan WL,
Leung BP,
Huang FP,
Wheeler R,
Piedrafita D,
Robinson JH,
Liew FY.
Selective expression of a stable cell surface molecule
on type 2 but not type 1 helper T cells.
J Exp Med
1998;
187:
787-794
16.
Löhning M,
Stroehmann A,
Coyle AJ,
Grogan JL,
Lin S,
Gutierrez-Ramos JC,
Levinson D,
Radbruch A,
Kamradt T.
T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function.
Proc Natl Acad Sci USA
1998;
95:
6930-6935
17.
Coyle AJ,
Lloyd C,
Tian J,
Nguyen T,
Erikkson C,
Wang L,
Ottoson P,
Persson P,
Delaney T,
Lehar S, et al
.
Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung
mucosal immune responses.
J Exp Med
1999;
190:
895-902
18.
Oshikawa K,
Kuroiwa K,
Tago K,
Iwahana H,
Yanagisawa K,
Ohno S,
Tominaga SI,
Sugiyama Y.
Elevated soluble ST2 protein levels in sera
of patients with asthma with an acute exacerbation.
Am J Respir Crit
Care Med
2001;
164:
277-281
19. Kuroiwa K, Li H, Tago K, Iwahana H, Yanagisawa K, Komatsu N, Oshikawa K, Sugiyama Y, Arai T, Tominaga S. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma 2000; 19: 151-159 [Medline].
20. Robinson DS, Ying S, Taylor IK, Wangoo A, Mitchell DM, Kay AB, Hamid Q, Shaw RJ. Evidence for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation in pulmonary tuberculosis. Am J Respir Crit Care Med 1994; 149: 989-993 [Abstract].
21. Oshikawa K, Sugiyama Y. Elevated soluble CD26 levels in patients with tuberculous pleurisy. Int J Tuberc Lung Dis 2001; 9: 868-872 .
22. Light RW. Pleural diseases, 2nd ed. Philadelphia: Lea & Febiger; 1990.
23.
Chen YM,
Yang WK,
Ting CC,
Tsai WY,
Yang DM,
Whang-Peng J,
Perng RP.
Cross regulation by IL-10 and IL-2/IL-12 of the helper T
cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients.
Chest
1997;
112:
960-966
24. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146 [Medline].
25. Chen YM, Tsai CM, Whang-Peng J, Perng RP. Interleukin-7 and interleukin-12 have different effects in rescue of depressed cellular immunity: comparison of malignant and tuberculous pleural effusions. J Interferon Cytokine Res 2001; 21: 249-256 [Medline].
26. Chen YM, Yang WK, Whang-Peng J, Tsai CM, Perng RP. An analysis of cytokine status in the serum and effusions of patients with tuberculosis and lung cancer. Lung Cancer 2001; 31: 25-30 [Medline].
27. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, Strieter RM. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994; 145: 18-25 [Abstract].
28.
Frankenberger M,
Passlick B,
Hofer T,
Siebeck M,
Maier KL,
Ziegler-Heitbrock LH.
Immunologic characterization of normal human pleural macrophages.
Am J Respir Cell Mol Biol
2000;
23:
419-426
29. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8: 275-283 [Medline].
30. Howard M, O'Garra A, Ishida H, de Waal Malefyt R, de Vries J. Biological properties of interleukin 10. J Clin Immunol 1992;12:239-247.
31.
Oshikawa K,
Shi F,
Rakhmilevich AL,
Sondel PM,
Mahvi DM,
Yang NS.
Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA.
Proc Natl Acad Sci
USA
1999;
96:
13351-13356
32. Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang N, Mahvi DM. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer. Hum Gene Ther 2001; 12: 149-160 [Medline].
33.
Mohammed KA,
Nasreen N,
Ward MJ,
Antony VB.
Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural
mesothelial cells.
Am J Respir Crit Care Med
1999;
159:
1653-1659
34. Antony VB, Godbey SW, Kunkel SL, Hott JW, Hartman DL, Burdick MD, Strieter RM. Recruitment of inflammatory cells to the pleural space: chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol 1993; 151: 7216-7223 [Abstract].
This article has been cited by other articles:
![]() |
J. L. Januzzi Jr, W. F. Peacock, A. S. Maisel, C. U. Chae, R. L. Jesse, A. L. Baggish, M. O'Donoghue, R. Sakhuja, A. A. Chen, R. R.J. van Kimmenade, et al. Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea: Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study J. Am. Coll. Cardiol., August 14, 2007; 50(7): 607 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jiang, H.-Z. Shi, Q.-L. Liang, S.-M. Qin, and X.-J. Qin Diagnostic Value of Interferon-{gamma} in Tuberculous Pleurisy: A Metaanalysis Chest, April 1, 2007; 131(4): 1133 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Okamoto, Y. Hasegawa, T. Hara, N. Hashimoto, K. Imaizumi, K. Shimokata, and T. Kawabe T-Helper Type 1/T-Helper Type 2 Balance in Malignant Pleural Effusions Compared to Tuberculous Pleural Effusions Chest, December 1, 2005; 128(6): 4030 - 4035. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Atanackovic, A. Block, A. de Weerth, C. Faltz, D. K. Hossfeld, and S. Hegewisch-Becker Characterization of Effusion-Infiltrating T Cells: Benign versus Malignant Effusions Clin. Cancer Res., April 15, 2004; 10(8): 2600 - 2608. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tajima, K. Oshikawa, S.-i. Tominaga, and Y. Sugiyama The Increase in Serum Soluble ST2 Protein Upon Acute Exacerbation of Idiopathic Pulmonary Fibrosis Chest, October 1, 2003; 124(4): 1206 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. Weinberg, M. Shimpo, S. Hurwitz, S.-i. Tominaga, J.-L. Rouleau, and R. T. Lee Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker Circulation, February 11, 2003; 107(5): 721 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Tobin Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 356 - 370. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |